Last reviewed · How we verify
Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?
NA trial testing Local Anesthetics Lidocaine in Carpal Tunnel Syndrome in 140 participants. Completed in 1 December 2022.
| Lead sponsor | University of Saskatchewan |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 140 |
| Start date | 1 July 2021 |
| Primary completion | 1 December 2022 |
| Estimated completion | 1 December 2022 |
| Sites | 1 location across Canada |
University of Saskatchewan
18 and older, any sex, with Carpal Tunnel Syndrome. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Severity of pain as measured by the Visual Analogue Scale. This tool asks patients to rate their post-operative pain level from 0 to 10. 0 represents no pain, while 10 represents the worst possible pain.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 1.16 | ± 1.83 |
| Bupivacaine | 0.92 | ± 1.61 |
Severity of pain as measured by the Visual Analogue Scale. This tool asks patients to rate their post-operative pain level from 0 to 10. 0 represents no pain, while 10 represents the worst possible pain.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 2.16 | ± 2.23 |
| Bupivacaine | 1.54 | ± 1.98 |
Severity of pain as measured by the Visual Analogue Scale. This tool asks patients to rate their post-operative pain level from 0 to 10. 0 represents no pain, while 10 represents the worst possible pain.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 3.19 | ± 2.29 |
| Bupivacaine | 2.29 | ± 2.35 |
Severity of pain as measured by the Visual Analogue Scale. This tool asks patients to rate their post-operative pain level from 0 to 10. 0 represents no pain, while 10 represents the worst possible pain.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 3.87 | ± 2.24 |
| Bupivacaine | 2.92 | ± 2.30 |
Severity of pain as measured by the Visual Analogue Scale. This tool asks patients to rate their post-operative pain level from 0 to 10. 0 represents no pain, while 10 represents the worst possible pain.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 3.81 | ± 2.32 |
| Bupivacaine | 3.38 | ± 2.42 |
Severity of pain as measured by the Visual Analogue Scale. This tool asks patients to rate their post-operative pain level from 0 to 10. 0 represents no pain, while 10 represents the worst possible pain.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 3.22 | ± 2.22 |
| Bupivacaine | 3.38 | ± 2.35 |
Number of Tylenol and Ibuprofen tablets taken post-operatively within the first 24 hours. This was not measured on a scale. Patients were asked to count the total number of Tylenol (500mg) and Ibuprofen (200mg) tablets they consumed within the first 24 hours after surgery.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 7.45 | ± 4.70 |
| Bupivacaine | 7.31 | ± 4.57 |
Number of Tylenol and Ibuprofen tablets taken post-operatively within the first 24 hours. This was not measured on a scale. Patients were asked to count the total number of Tylenol (500mg) and Ibuprofen (200mg) tablets they consumed within the first 72 hours after surgery.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 14.5 | ± 11.8 |
| Bupivacaine | 13 | ± 8.9 |
Presence of post-operative numbness in any finger (thumb, index, middle, ring, or little finger). Patients answer "yes" or "no" to numbness.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 55 | |
| Bupivacaine | 58 |
Presence of post-operative numbness in any finger (thumb, index, middle, ring, or little finger). Patients answer "yes" or "no" to numbness.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 55 | |
| Bupivacaine | 64 |
Presence of post-operative numbness in any finger (thumb, index, middle, ring, or little finger). Patients answer "yes" or "no" to numbness.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 43 | |
| Bupivacaine | 63 |
Presence of post-operative numbness in any finger (thumb, index, middle, ring, or little finger). Patients answer "yes" or "no" to numbness.
| Group | Value | 95% CI |
|---|---|---|
| Lidocaine | 31 | |
| Bupivacaine | 59 |
This study is being conducted to determine whether addition of a longer-acting local anesthetic to our current anesthetic protocol improves the post-operative pain after carpal tunnel release. Participants undergoing carpal tunnel release (CTR) will be randomly assigned to one of two groups: the standard anesthetic or the longer-acting anesthetic. Participants will not be aware of their assignment. Carpal tunnel release will be performed in the standard fashion at our hospital. Participants will record their post-operative pain on a visual scale at 2, 4, 6, 8, and 10 hours after surgery. They will also record the location of their post-operative numbness at the same time intervals. The day after surgery, a research nurse will call each participant to inquire about their post-operative pain scores and numbness. Participants will also be asked about their consumption of oral painkillers (e.g. Tylenol, ibuprofen) during the first 24 hours. Participants will be re-assessed 3 months after surgery to evaluate improvement in carpal tunnel symptoms. Participants who wish to have carpal tunnel release on both wrists will be randomized to receive one type of anesthetic for the first side and will receive the other anesthetic for the second side. They will not be made aware of which medication is used for each side. This will allow us to directly compare the difference in pain experience between the two anesthetics. We hypothesize that use of a longer-acting local anesthetic will lead to decreased post-operative pain, especially in the first 4-8 hours after surgery.
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04833777.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing